Press Releases for CBLI

Press Releases
Cleveland BioLabs Receives First U.S. Patent Allowance for Its Radiation Protection Drug Protectan CBLB502
Department of Defense Releases Further Funding to Cleveland BioLabs Under $8.8 Million Contract for Development Studies on Protectan CBLB502
Cleveland BioLabs Management Reviews Recent Highlights and Milestones at Annual Meeting
Cleveland BioLabs Concludes Initial Phase I Safety and Tolerability Study for CBLB502
Cleveland BioLabs Submits Response to Department of Defense Sources Sought Notice for Radiological and Nuclear Medical Countermeasures
Cleveland BioLabs Signs Term Sheet for Joint Venture to Develop Curaxin Compounds for Cancer Applications
Oncogene Publishes Cleveland BioLabs Paper on Mechanism of Action of Curaxins
Cleveland BioLabs Formally Terminates Boston Stock Exchange Listing
Cleveland BioLabs Updates Financial Condition Following Completion of Private Placement and Streamlining of Operations
Cleveland BioLabs Concludes Private Placement of Series D Preferred Stock and Common Stock Warrants
Cleveland BioLabs to Host Investor Update Conference Call on March 31
Cleveland Biolabs Consummates Private Placement of Series D Preferred Stock and Common Stock Warrants - Mar 23 2009 8:37AM
Cleveland BioLabs Consummates Private Placement of Series D Preferred Stock and Common Stock Warrants - Feb 17 2009 8:25AM
Zacks Analyst Blog Highlights: Cleveland BioLabs, First Advantage Corporation, Nabors Industries Ltd., Johnson & Johnson and Shutterfly, Inc.
Cleveland BioLabs Completes Dosing of Fourth Cohort in Initial Safety Study for Protectan CBLB502
Cleveland BioLabs Reports Advances in Curaxin Anticancer Program
Cleveland BioLabs Announces Appointment of International Expert in Chemical, Biological and Radiological/Nuclear Threat Countermeasures as Senior Vice President of Public Health and Government Services
Zacks Bull and Bear of the Day Highlights: Inter Parfums, JC Penney, Cleveland BioLabs, O2Micro International and Honda
Zacks Bull and Bear of the Day Highlights: Inter Parfums, JC Penney,Cleveland BioLabs, O2Micro International and Honda
Cleveland BioLabs to Present at Rodman and Renshaw 10th Annual Healthcare Conference
Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction of Myelosuppression in Mouse Model of Chemotherapy
Cleveland BioLabs Receives Letter From NASDAQ Citing Non-Compliance With Global Market Listing Requirements
Cleveland BioLabs to Present at 2008 BIO Investor Forum
Cleveland BioLabs Doses First Healthy Volunteer in Initial Safety Study for Protectan CBLB502
Cleveland BioLabs to Present at Maxim Group Growth Conference
Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day
Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) Awards Cleveland BioLabs Contract to Develop Protectan CBLB502
National Institute of Allergy and Infectious Diseases Awards Cleveland BioLabs Grant for Protectan CBLB502 Research in Mitigation of Radiation Damage
Cleveland BioLabs and Cleveland Clinic Demonstrate Accelerated Recovery of Limb Function With Protectan CBLB502 in Tourniquet Injury Model
Cleveland BioLabs Receives Notice of Allowance From FDA to Commence Clinical Testing With Protectan CBLB502
Cleveland BioLabs Featured in Note From CEO of The Robins Group, LLC
Cleveland BioLabs to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference - Jun 1 2008 3:58PM
Cleveland BioLabs Completes Recruitment for Phase II Hormone-Refractory Prostate Cancer Trial - Jun 1 2008 3:57PM
Buyins.net Initiates Coverage on Cleveland BioLabs With SqueezeTrigger Price of $7.41 - Jun 1 2008 3:57PM
Cleveland BioLabs Featured in "Gene Marcial's 7 Commandments of Stock Investing" - Jun 1 2008 3:57PM
Cleveland BioLabs Management Reviews 2008 Highlights and Milestones at Annual Meeting
Cleveland BioLabs to Highlight Recent Achievements and Provide Update on Development Strategy on April 17 Conference Call
WBB Securities Upgrades Cleveland BioLabs to Strong Buy and Reiterates $13 Price Target
Science Magazine Publishes Cleveland BioLabs Breakthrough Paper on Protectan CBLB502's Radioprotective Activity
Cleveland BioLabs to Submit Protectan CBLB502 for BARDA BAA for Development of Therapies to Protect Civilian Population From Radiation Exposure
Department of Defense Awards Cleveland BioLabs Contract to Develop Protectan CBLB502